We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other German stocks. In Germany, the economic growth is based on industry. According to ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...

Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.26% to 5,942.47 ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The BioNTech SE ADR BNTX inched 0.57% higher to $122.85 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.54% to 5,827.04 ...